Elan announces launch of extended release Ampyra in U.S.; Pfizer, BMS oral anti-clot drug shows promise;

> Pfizer and Bristol-Myers Squibb's oral anticoagulant apixaban achieved positive results in a late-stage Advance-2 study. Apixaban was shown to be statistically superior to 40 mg once daily enoxaparin (Lovenox) in reducing the incidence of venous thromboembolism in patients undergoing total knee replacement surgery. The study results also showed lower rates of bleeding in patients treated with apixaban compared to enoxaparin. BMS release

> Following its approval earlier this year, Elan Drug Technologies has announced the launch of Ampyra (dalfampridine) by Acorda Therapeutics in the U.S. as a treatment to improve walking in patients with multiple sclerosis. The first NDA approved and launched incorporating Elan's MXDAS technology, Ampryra was developed using a hydrophilic matrix, which controls the rate of release of dalfampridine through a process of diffusion and erosion in the gastrointestinal tract. Release

> Genentech's submission of an IND application with the FDA for an antibody drug conjugate utilizing Seattle Genetics' technology for the treatment of cancer marks a milestone in the collaborative effort between the two companies. ADCs are empowered monoclonal antibodies that carry potent, cell-killing drugs. Seattle Genetics has developed proprietary technology employing synthetic, highly potent drugs that can be attached to antibodies through stable linker systems. Genentech release

> Mallinckrodt, a Covidien company, has launched its oral transmucosal fentanyl citrate (CII) to distributors across the country. A generic alternative to the branded ACTIQ, the product is a solid formulation of fentanyl that resembles a lozenge on a handle. Oral Transmucosal Fentanyl Citrate, a Class II controlled substance, is an opioid analgesic indicated only for the management of breakthrough cancer pain in patients 16 years of age and older with malignancies. Covidien release